Decheng Capital LLC Sells 696,435 Shares of Zentalis Pharmaceuticals, Inc. $ZNTL

Decheng Capital LLC decreased its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 34.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 1,323,327 shares of the company’s stock after selling 696,435 shares during the period. Zentalis Pharmaceuticals accounts for about 0.4% of Decheng Capital LLC’s portfolio, making the stock its 16th largest holding. Decheng Capital LLC’s holdings in Zentalis Pharmaceuticals were worth $1,535,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at $31,000. Alpine Global Management LLC bought a new stake in shares of Zentalis Pharmaceuticals in the first quarter valued at about $48,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at about $38,000. Public Employees Retirement System of Ohio grew its stake in shares of Zentalis Pharmaceuticals by 351.7% in the second quarter. Public Employees Retirement System of Ohio now owns 36,700 shares of the company’s stock valued at $43,000 after acquiring an additional 28,576 shares in the last quarter. Finally, State of Wyoming increased its position in Zentalis Pharmaceuticals by 30.1% during the first quarter. State of Wyoming now owns 45,176 shares of the company’s stock worth $72,000 after acquiring an additional 10,460 shares during the period.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL opened at $1.38 on Thursday. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.01 and a 1 year high of $4.00. The stock has a market capitalization of $99.71 million, a price-to-earnings ratio of -0.67 and a beta of 1.75. The company’s 50 day simple moving average is $1.49 and its 200 day simple moving average is $1.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.12. As a group, analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Leerink Partners reissued a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Wedbush reiterated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. Morgan Stanley dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, November 12th. Finally, Wells Fargo & Company cut their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $4.53.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.